Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin

The Journal of Antibiotics
Gongming ShiXulei Zhang

Abstract

Antibiotic activity can differ depending on whether the bacterial target is extracellular or intracellular. To determine extracellular and intracellular activities of sitafloxacin (STX) against Staphylococcus aureus in comparison with levofloxacin (LVX) and moxifloxacin (MXF) in vivo and in vitro, three S. aureus strains (ATCC25923, 29213, 43300) were evaluated. MIC, MBC and mutant prevention concentration (MPC) of the test quinolone for S. aureus were determined by microdilution in broth, and intracellular activity was determined in RAW264.7 cells after phagocytosis of bacteria. Cellular quinolone accumulation was determined by HPLC. The time- and concentration-kill relationships were examined in vitro (in broth and in RAW264.7 cells, respectively) and in vivo by use of a mouse peritonitis model. The results showed that the activity of STX in broth cultures, including the MIC, MBC, MPC and the time- and concentration-kill relationships, were greater for STX than those for LVX and MXF. In particular, STX exhibited the strongest activity against intramacrophage S. aureus. The intracellular effects could be ranked in the following order as the mean change in the log10 number of cfu ml(-1) (log10 cfu ml(-1)) between treated and un...Continue Reading

References

Mar 21, 1998·Archives of Internal Medicine·A G JensenN Frimodt-Møller
Jul 25, 2000·Postgraduate Medical Journal·J Ciampolini, K G Harding
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·X Zhao, K Drlica
Oct 12, 2001·Apoptosis : an International Journal on Programmed Cell Death·M EsenE Gulbins
Jun 21, 2005·Emerging Infectious Diseases·Matthew J KuehnertDaniel B Jernigan
Jun 24, 2005·JAMA : the Journal of the American Medical Association·Vance G FowlerUNKNOWN ICE Investigators
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Maritza Barcia-MacayFrançoise Van Bambeke
Mar 18, 2006·BMC Infectious Diseases·Michael PedersenAllan G Jensen
May 4, 2007·International Journal of Antimicrobial Agents·Anna M Ferrara
Feb 19, 2009·Antimicrobial Agents and Chemotherapy·Anne SandbergNiels Frimodt-Møller
Apr 21, 2011·Drugs·Gillian M Keating

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.